Gene therapy injection for wet age-related macular degeneration
Part of Eyes & vision clinical trials.
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 50 years or older.
- You have wet AMD with active new blood vessels in the center of your vision, confirmed by a specialist.
- You have either had no previous anti-VEGF injections, or no more than 4 injections in the last 6 months with good response.
- Your vision in the study eye must be between 20/320 and 20/32 on an eye chart.
- The central thickness of your retina must be 500 microns or less.
- You cannot have other causes of new blood vessels, scars, bleeding in the center of vision, or certain other eye conditions like uncontrolled glaucoma or inflammation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene therapy injection (IXO-vec) for people with wet age-related macular degeneration (nAMD). It aims to reduce the need for frequent eye injections by helping the eye make its own medicine to block the growth of harmful blood vessels.
This study tests a one-time gene therapy called LX102 for wet age-related macular degeneration (AMD). It may reduce the need for frequent eye injections and help preserve vision.
This study tests an investigational gene therapy (called CRISPR/Cas13) given as an injection into the eye for people with wet age-related macular degeneration (nAMD). It aims to see if the treatment is safe and if it can help by targeting the cause of the disease.
This trial tests a new eye injection called GB10 for people with wet AMD, a condition that causes rapid vision loss. The goal is to see if it is safe and works to improve or stabilize vision.
This study tests a new gene therapy called 4D-150 for people with wet age-related macular degeneration (AMD). It aims to reduce the need for frequent anti-VEGF injections by delivering a long-lasting treatment into the eye.
This trial tests a one-time gene therapy injection into the eye for adults with diabetic macular edema (DME), a condition where fluid builds up in the retina and blurs vision. The goal is to reduce the need for frequent eye injections and help maintain vision over time.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.